MX362485B - Nuevos inhibidores de rock. - Google Patents

Nuevos inhibidores de rock.

Info

Publication number
MX362485B
MX362485B MX2015005459A MX2015005459A MX362485B MX 362485 B MX362485 B MX 362485B MX 2015005459 A MX2015005459 A MX 2015005459A MX 2015005459 A MX2015005459 A MX 2015005459A MX 362485 B MX362485 B MX 362485B
Authority
MX
Mexico
Prior art keywords
inhibitors
treatment
relates
rock inhibitors
prophylaxis
Prior art date
Application number
MX2015005459A
Other languages
English (en)
Other versions
MX2015005459A (es
Inventor
Leysen Dirk
Boland Sandro
Pierre Jean Bourin Arnaud
Defert Olivier
Original Assignee
Amakem Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amakem Nv filed Critical Amakem Nv
Publication of MX2015005459A publication Critical patent/MX2015005459A/es
Publication of MX362485B publication Critical patent/MX362485B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)

Abstract

La presente invención se refiere a nuevos inhibidores de cinasa, más específicamente inhibidores de ROCK, a composiciones, en particular farmacéuticas, que contienen dichos inhibidores y a usos de tales inhibidores en el tratamiento y profilaxis de la enfermedad. En particular, la presente invención se refiere a nuevos inhibidores de ROCK, a composiciones, en particular farmacéuticas, que contienen dichos inhibidores y a usos de tales inhibidores en el tratamiento y profilaxis de la enfermedad. Además, la invención se refiere a métodos de tratamiento y al uso de dichos compuestos en la fabricación de un medicamento para la aplicación a una cantidad de indicaciones terapéuticas, incluidas disfunción sexual, enfermedades inflamatorias, enfermedades oftálmicas y enfermedades respiratorias. Los compuestos de la invención muestran características de fármacos blandos, es decir, se inactivan rápidamente al entrar en la circulación sistémica. Por lo tanto, permiten la exposición sistémica reducida a los inhibidores de ROCK activos funcionalmente.
MX2015005459A 2012-10-31 2013-10-31 Nuevos inhibidores de rock. MX362485B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12190859 2012-10-31
PCT/EP2013/072774 WO2014068035A1 (en) 2012-10-31 2013-10-31 Novel rock inhibitors

Publications (2)

Publication Number Publication Date
MX2015005459A MX2015005459A (es) 2015-07-21
MX362485B true MX362485B (es) 2019-01-21

Family

ID=47148627

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005459A MX362485B (es) 2012-10-31 2013-10-31 Nuevos inhibidores de rock.

Country Status (21)

Country Link
US (1) US9394286B2 (es)
EP (1) EP2914590B1 (es)
JP (1) JP6205425B2 (es)
KR (1) KR102242280B1 (es)
CN (1) CN104822676B (es)
AU (1) AU2013340854B2 (es)
BR (1) BR112015009504A2 (es)
CA (1) CA2922312C (es)
DK (1) DK2914590T3 (es)
EA (1) EA026629B1 (es)
ES (1) ES2617495T3 (es)
HK (1) HK1213550A1 (es)
IL (1) IL238391A (es)
IN (1) IN2015DN04311A (es)
MX (1) MX362485B (es)
NZ (1) NZ708526A (es)
PL (1) PL2914590T3 (es)
PT (1) PT2914590T (es)
SG (1) SG11201503134WA (es)
WO (1) WO2014068035A1 (es)
ZA (1) ZA201503544B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
US11202773B2 (en) * 2015-04-20 2021-12-21 University Of Houston System Locally bioavailable drugs
WO2017114275A1 (zh) * 2015-12-31 2017-07-06 成都先导药物开发有限公司 一种抑制rock的化合物及其制备方法与应用
EP3693380A1 (en) * 2019-02-11 2020-08-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Dual inhibition of plexin-b1 and plexin-b2
WO2023085369A1 (ja) 2021-11-11 2023-05-19 学校法人同志社 角膜内皮細胞の凍結保存製剤およびその製造法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
US8071779B2 (en) 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
EP2317849A4 (en) 2008-06-26 2011-11-02 Inspire Pharmaceuticals Inc PROCESS FOR THE TREATMENT OF LUNG DISEASES WITH RHO KINASE INHIBITOR COMPOUNDS
US20090325959A1 (en) 2008-06-26 2009-12-31 Vittitow Jason L Method for treating ophthalmic diseases using rho kinase inhibitor compounds
US20090325960A1 (en) 2008-06-26 2009-12-31 Fulcher Emilee H Method for treating inflammatory diseases using rho kinase inhibitor compounds
US20100204210A1 (en) 2008-12-04 2010-08-12 Scott Sorensen Method for treating pulmonary diseases using rho kinase inhibitor compounds
WO2011075415A1 (en) * 2009-12-14 2011-06-23 Inspire Pharmaceuticals, Inc. Bridged bicyclic rho kinase inhibitor compounds, composition and use
WO2012012282A1 (en) * 2010-07-19 2012-01-26 Inspire Pharmaceuticals, Inc. Bifunctional rho kinase inhibitor compounds, composition and use
CA2803689A1 (en) * 2010-07-27 2012-02-02 Inspire Pharmaceuticals, Inc. Method for treating ophthalmic diseases using kinase inhibitor compounds in prodrug forms
GB201107223D0 (en) * 2011-04-29 2011-06-15 Amakem Nv Novel rock inhibitors

Also Published As

Publication number Publication date
IL238391A0 (en) 2015-06-30
IN2015DN04311A (es) 2015-10-16
KR20150084027A (ko) 2015-07-21
SG11201503134WA (en) 2015-05-28
NZ708526A (en) 2018-08-31
US9394286B2 (en) 2016-07-19
EP2914590A1 (en) 2015-09-09
CA2922312A1 (en) 2014-05-08
EA201590847A1 (ru) 2015-08-31
JP2015535270A (ja) 2015-12-10
DK2914590T3 (en) 2017-03-06
AU2013340854B2 (en) 2017-06-08
US20150299173A1 (en) 2015-10-22
KR102242280B1 (ko) 2021-04-20
AU2013340854A1 (en) 2015-06-11
ES2617495T3 (es) 2017-06-19
CN104822676A (zh) 2015-08-05
ZA201503544B (en) 2017-09-27
BR112015009504A2 (pt) 2017-07-04
PT2914590T (pt) 2017-02-27
MX2015005459A (es) 2015-07-21
EA026629B1 (ru) 2017-04-28
HK1213550A1 (zh) 2016-07-08
CN104822676B (zh) 2019-11-05
CA2922312C (en) 2020-10-20
JP6205425B2 (ja) 2017-09-27
PL2914590T3 (pl) 2017-06-30
IL238391A (en) 2017-08-31
EP2914590B1 (en) 2016-11-30
WO2014068035A1 (en) 2014-05-08

Similar Documents

Publication Publication Date Title
BR112015018168A2 (pt) inibidores de rock suaves
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
EA201492290A1 (ru) Составы и способы для вагинальной доставки антипрогестинов
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
WO2011107608A8 (en) Heterocyclic amides as rock inhibitors
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX2014002394A (es) Inhibidores de rock suaves, novedosos.
TW201129382A (en) Antibody formulation and therapeutic regimens
EA201370230A1 (ru) Новые ингибиторы rock
EA201500365A1 (ru) Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
NZ702253A (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
MX362485B (es) Nuevos inhibidores de rock.
EA201490417A1 (ru) Новые легкоразрушающиеся ингибиторы pde 4
GB201111427D0 (en) Novel bisindolylmaleimides, pan-pkc inhibitors
EA201490935A1 (ru) Терапевтическая комбинация мемантина и баклофена и содержащая их фармацевтическая композиция
TR201900156T4 (tr) Tüberküloz ve ilgili hastalıkların tedavisi için kinolil hidrazonlar.

Legal Events

Date Code Title Description
FG Grant or registration